Skip to content
Cure Ventures
  • People
  • Companies
  • Approach
  • About
    • Overview
    • News
    • Community
    • Careers
  • Contact
Cure Ventures
  • People
  • Companies
  • Approach
  • About
    • Overview
    • News
    • Community
    • Careers
  • Contact

Companies with Curative Ambition

Breakthrough is Just the Beginning for Our Entrepreneurs

Meet the Newest Member of Our Family Tree

Dr. Michael Aberman, CEO of XenImmune

Developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection. By leveraging the natural power of the immune response system, we are able to utilize fusion protein technology to attack difficult tumor targets throughout the body.

Read Michael's Story

Cure Portfolio Companies

  • View All
Loading...

Developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection. By leveraging the natural power of the immune response system, we are able to utilize fusion protein technology to attack difficult tumor targets throughout the body.

Focus/Therapeutic Area:

Oncology

Stage/Status:

Seed

Website:

https://www.xenimmune.com

With a novel approach to precision oncology, Tasca Therapeutics is unlocking post-translational modification of proteins by utilizing our state-of-the-art chemical biology and computational approaches, and combining with inhibition at key metabolic nodes to generate drugs for previously considered undruggable targets. Tasca is focused on using its proprietary platform to develop small molecule drugs for hard-to-treat oncology indications.

Focus/Therapeutic Area:

Oncology

Stage/Status:

Seed

Website:

https://www.tascatx.com

Stealth Mode Newco – New Protein Factors / Neurodegenerative Disease

Stealth Mode Newco – Musculoskeletal Disease

Stealth Mode Newco – Engineered Proteins Towards Cancer

Stealth Mode Newco – Multiple Chronic Disease Targets

End of content

No more pages to load

Our Standard Approach

Embracing Evidence. Increasing Success. Saving Lives.

How We Go All-In

© 2023 Cure Ventures

  • People
  • Companies
  • Approach
  • About
  • News
  • Community
  • Careers
  • Contact
  • Privacy Policy
  • Investor Login